The genetic modification of freshly aspirated bone marrow may provide convenient tools to enhance the regenerative capacities of cartilage defects compared with the complex manipulation of isolated progenitor cells. In the present study, we examined the ability and safety of recombinant adeno-associated virus (rAAV) serotype 2 vectors to deliver various reporter gene sequences in primary human bone marrow aspirates over time without altering the chondrogenic processes in the samples. The results demonstrate that successful rAAV-mediated gene transfer and expression of the lacZ and red fluorescent protein marker genes were achieved in transduced aspirates at very high efficiencies (90-94%) and over extended periods of time (up to 125 days) upon treatment with hirudin, an alternative anticoagulant that does not prevent the adsorption of the rAAV-2 particles at the surface of their targets compared with heparin. Application of rAAV was safe, displaying neither cytotoxic nor detrimental effects on the cellular and proliferative activities or on the chondrogenic processes in the aspirates especially using an optimal dose of 0.5 mg ml − 1 hirudin, and application of the potent SOX9 transcription factor even enhanced these processes while counteracting hypertrophic differentiation. The current findings demonstrate the clinical value of this class of vector to durably and safely modify bone marrow aspirates as a means to further develop convenient therapeutic approaches to improve the healing of cartilage defects.
INTRODUCTION
Damage to the articular cartilage is a prevalent, major unsolved problem in a variety of joint disorders, 1 including joint trauma 2 and osteoarthritis. 3 Since cartilage is an avascular tissue, it does not have plain access to chondroprogenitor cells that can support and participate in regenerative processes. [4] [5] [6] [7] Therapeutic interventions such as marrow stimulation techniques by perforation of the subchondral bone (microfracture, Pridie drilling and abrasion arthroplasty) have been developed to address this issue, allowing for the invasion of cells from the bone marrow to repopulate a defect and contribute to its repair. [7] [8] [9] Yet, such options do not predictably restore an original cartilage structure and function in the lesion as the newly formed tissue is mainly of fibrocartilaginous nature. 7, 8, 10, 11 Although this type of cartilage is clinically useful, allowing for a reduction of pain and an improved joint function, it is poorly organized, of lesser mechanical quality and usually degrades over time and under loading. 12 Administration of agents capable of modulating chondrogenic differentiation pathways in progenitor cells is an attractive approach to improve the quality of the healing response of cartilage to injury. Gene therapy is a powerful tool to promote the expression of therapeutic agents in their targets over sustained, relevant periods of time either via direct gene vector application or by indirect procedures using genetically modified cells. [4] [5] [6] 13, 14 Although direct approaches are relatively simple to execute, those based on indirect procedures are considered safer as no free vector particles are introduced in the recipient, having the further advantage to enhance the cellularity like in the case of large cartilage lesions. Nevertheless, ex vivo gene transfer methods include steps of cell harvesting and expansion, making them more complex and laborious. The identification of alternative, convenient gene delivery procedures is thus under active investigation such as options based on the supply of whole bone marrow aspirates 15 instead of isolated progenitor cells. In this regard, different groups evaluated the feasibility of modifying rabbit and sheep bone marrow aspirates via adenoviral gene transfer, reporting marker gene expression in vitro (up to 21 days) 16, 17 and in cartilage defects in vivo (up to 7 days). 17 Although such vectors generally allow only for short-term transgene expression levels and induce undesirable immune responses in the host, [4] [5] [6] 14 those based on the adeno-associated virus (AAV) appear more advantageous as recombinant AAV (rAAV) vectors can efficiently, safely and durably transduce most cells of the musculoskeletal system among which bone marrow-derived mesenchymal stem cells (MSCs) both in vitro and in cartilage defects in vivo. [18] [19] [20] [21] [22] Furthermore, AAV is a nonpathogenic, replication-defective human parvovirus, 23 which is much less immunogenic than adenoviruses. [4] [5] [6] 14 As a matter of fact, there is no evidence in the literature showing that rAAV vectors are capable of genetically modifying primary human bone marrow aspirates. In the present study, we therefore examined the efficacy and duration of transgene expression mediated by rAAV-2 vectors in such aspirates and tested whether gene transfer with this class of vector modulates 1 the chondrogenic differentiation potential in transduced samples. We performed our evaluations in the absence of heparin, an anticoagulant present at the time of collection that is known to inhibit the attachment of rAAV-2 particles at the surface of human cell lines by binding to the cell membrane receptor of the virus (a heparin sulfate proteoglycan), consequently impairing their functionality. [24] [25] [26] Instead, we replaced heparin with hirudin (an alternative anticoagulant used in patients with heparin-induced thrombocytopenia) 27 that does not display such inhibitory effects. 24, 25 Our data show that rAAV are particularly well suited to persistently modify primary human bone marrow aspirates treated with hirudin in contrast with heparin, without impeding the chondrogenic differentiation processes. Such processes could be even activated when applying the chondrogenic transcription factor SOX9 that was further capable of reducing undesirable hypertrophic maturation. The use of bone marrow aspirates modified by rAAV thus has strong value for therapeutic genebased approaches to treat articular cartilage defects.
RESULTS
Inhibitory effects of heparin on rAAV-mediated gene transfer in primary human bone marrow aspirates As heparin was reported to strongly interfere with rAAV-2-mediated gene transfer in human cell lines, [24] [25] [26] our goal was to first examine whether this anticoagulant displayed similar effects in primary human bone marrow aspirates.
To test this hypothesis, we evaluated the efficacy of rAAV-lacZmediated gene transfer in samples treated or not with heparin using increasing doses of vector and compared with untransduced (control) samples. A quantitative analysis of lacZ expression by Beta-Glo assay (Promega, Mannheim, Germany) revealed that rAAV transduction was inhibited in heparin-treated samples at any vector dose applied whereas effective, dose-dependent β-galactosidase (β-gal) activities were detectable in nonanticoagulated aspirates following administration of rAAV-lacZ (always P ⩽ 0.05; Figure 1 ). No signal was evidenced in the control samples, independently in the presence of heparin (data not shown).
Use of hirudin as an alternative anticoagulant that allows for the effective modification of primary human bone marrow aspirates via rAAV gene delivery To circumvent the inhibitory effects of heparin on the transduction of human bone marrow aspirates with rAAV-2 vectors, samples were collected in the presence of hirudin instead of heparin 27 using concentrations previously tested in human cell lines 24, 25 , revealing no difference in the aspect of the samples (Figure 2a) .
We first examined whether hirudin impaired the early adsorption of rAAV on primary human bone marrow aspirates. An analysis by X-gal staining of aspirates 2 days following application of rAAV-lacZ at a high vector dose (40 μl) 18, 28 revealed that the presence of this alternative anticoagulant did not prevent rAAVmediated gene transfer and expression compared with control samples, regardless of the concentration of hirudin provided (Figure 2b ). The transduction efficiencies reached up to 90-97% compared with control samples (always ⩽ 4%) as noted by morphometric analyses performed on macroscopic views and histological sections from aspirates (Figures 2b-d) .
Evaluation of the efficacy of transgene expression in hirudintreated aspirates transduced with rAAV-lacZ over a longer period of time (21 days) further revealed that sustained, elevated levels of β-gal activities were achieved in extended lacZ-transduced cultures compared with control samples especially when applying the anticoagulant at a concentration of 0.5 mg ml − 1 (up to 7.5-fold difference relative to the untransduced aspirates; P ⩽ 0.030; Figure 3 : top panels). Interestingly, a plateau of expression was rapidly reached using the lowest dose applied and well maintained at this concentration of hirudin (P ⩾ 0.329). At lower or higher concentrations of anticoagulant (0.2 or 5 mg ml
), the levels of expression were inferior to those achieved at 0.5 mg ml − 1 or the fold increases to the untransduced controls were lower than in such a condition (1.5-fold using 40 μl rAAV versus no vector treatment at 5 mg ml − 1 hirudin), although statistical significance was not reached (P ⩾ 0.193). When the samples were processed to evaluate possible undesirable effects of the different treatments upon the proliferative activities in the aspirates by WST-1 assay ( Figure 3 : lower panels), neither deleterious effects of hirudin nor of the vector were seen at any concentration of anticoagulant or of vector applied (P ⩾ 0.102), revealing instead higher rates of proliferation in the presence of rAAV (up to 3.6-fold difference, P ⩽ 0.035) in good agreement with previous findings in isolated human cells transduced with equivalent (low) amounts of vector. 29 These results were corroborated by an analysis of cytotoxic events in the samples, showing no deleterious effects of the anticoagulant or of the vector treatment at any concentration or dose applied compared with conditions without hirudin and/or vector (always ⩽ 1% after 2 or 21 days, P ⩾ 0.089). Evaluation of transgene expression over extended periods of time in hirudintreated aspirates transduced with a high dose of rAAV-RFP (rAAVred fluorescent protein) vector (40 μl) finally demonstrated that a strong red fluorescent signal was still evidenced after 125 days (the longest time point evaluated) compared with control treatments (Figure 4) . Applying hirudin at a concentration of 0.5 mg ml − 1 allowed to generate a compact, intense RFP signal in the samples, stronger than in the aspirates treated at lower (0.2 mg ml − 1 ) or higher (5 mg ml − 1 ) concentrations of anticoagulant where the levels of fluorescence were also more sparse (0.2 mg ml − 1 ) or more rapidly decreased over time (5 mg ml − 1 ).
Primary human bone marrow aspirates treated with hirudin maintain their potential for chondrogenic differentiation In light of these findings, we selected hirudin at 0.5 mg ml − 1 as the best suited concentration for effective, safe and prolonged rAAV-mediated gene transfer and expression in primary human bone marrow aspirates. Application of rAAV-lacZ (40 μl) was performed compared with control transduction to test whether the presence of hirudin and of the vector itself affected the chondrogenic differentiation processes in aspirates maintained in defined medium. Successful chondrogenesis was seen in all aspirates as evidenced by intense toluidine blue staining and type-II collagen deposition on histological sections of aspirates ( Figure 5a ). Neither the presence of hirudin nor that of rAAV altered the potency of the samples for chondrogenesis compared with control conditions (absence of hirudin and of vector treatment), as confirmed by an histomorphometric analysis of the intensities of toluidine blue staining (76 ± 2%, 79 ± 2% and 76 ± 3% in untransduced aspirates collected without hirudin or treated with hirudin 0.5 mg ml − 1 and in lacZ-transduced hirudintreated aspirates, respectively, P ⩾ 0.277) and of immunostaining for type-II collagen (80 ± 2%, 83 ± 2% and 79 ± 1%, respectively, P ⩾ 0.187; Figure 5b ). Further analysis of potentially undesirable effects of the treatments revealed that neither the presence of hirudin nor of the rAAV vectors in the aspirates induced premature hypertrophy and terminal differentiation as observed by moderate immunostaining for type-X collagen on histological sections of aspirates (Figure 5a ), a result also confirmed by histomorphometric analysis (14 ± 3%, 11 ± 3% and 9 ± 2%, respectively, P ⩾ 0.110; Figure 5b) .
When a candidate rAAV vector carrying the potent chondrogenic SOX9 transcription factor was provided instead of lacZ at a similar concentration of hirudin, increased effects upon the chondrogenic features in the aspirates were noted by more intense toluidine blue staining and type-II collagen deposition compared with all other conditions (Figure 5a ), a finding confirmed by histomorphometry (95 ± 2% and 98 ± 1%, respectively, P ⩽ 0.001; Figure 5b ), revealing less voids and a more compact structure of the aspirates. Also notably, application of rAAV-FLAG-hsox9 further decreased the expression of type-X collagen relative to all other conditions (4 ± 1%, P ⩽ 0.001; Figures 5a and b). These effects of the SOX9 treatment were associated with enhanced expression levels of the transgene compared with the controls (85 ± 2% versus 10 ± 2%, 11 ± 3% and 10 ± 1%, P ⩽ 0.001; Figure 5a ).
DISCUSSION
The articular cartilage is an avascular, aneural tissue without lymphatic drainage that has a reduced capacity for self repair. Surgical interventions that make cells from the subchondral bone marrow accessible to a cartilage lesion do not allow for the production of an original, hyaline cartilage in the repair tissue. 7, 8, 10, 11 Active clinical and experimental research is ongoing to improve the course of the healing in such defects, often emphasizing on the implantation of isolated cells known to contribute to the repair process (chondrocytes and MSCs). [30] [31] [32] [33] Despite critical advances, such transplantation procedures require complex steps of cell extraction and expansion in culture prior to re-administration in the lesions and like for marrow stimulation techniques, they do not restore a native cartilage. In this regard, the use of whole bone marrow aspirates rather than the use of isolated cells, combined with a simple, effective step of gene transfer to activate the reparative processes in the defects is an attractive strategy for improved, clinically applicable treatments for cartilage lesions. Interestingly, genetic modification of bone marrow aspirates has been attempted in samples from rabbits and sheep by application of immunogenic adenoviral vectors that allowed for relatively short-term transgene expression levels (21 days in vitro and 7 days in vivo). 16, 17 Instead, vectors derived from the nonpathogenic, low immunogenic AAV human parvovirus are long known for their safe and persistent ability to transduce cells of the musculoskeletal system like chondrocytes and MSCs. [18] [19] [20] [21] [22] 28 Yet, little is known on the potential of rAAV-2 to deliver and overexpress gene sequences in bone marrow aspirates. In the present study, we thus evaluated the ability of this class of vector to promote marker gene expression in primary human bone marrow aspirates over time and tested whether such modification interfered with the chondrogenic differentiation processes in transduced samples.
Our data first demonstrate that a strong inhibition of the transduction via rAAV-2 was noted when the aspirates were collected in the presence of heparin, corroborating previous findings showing that this anticoagulant prevents the adsorption of rAAV-2 particles at the surface of human cell lines. [24] [25] [26] Yet, such interference could be avoided when heparin was replaced with hirudin, 27 as application of this alternative compound allowed for early (2 days) and late (up to 21 days) transgene (lacZ) expression in modified aspirates compared with control samples, revealing very high transduction efficiencies (up to 90-94%), again consistent with the properties of this reagent. 24, 25 The results of ).
rAAV gene transfer in human bone marrow aspirates A Rey-Rico et al whole period of evaluation. Most remarkably, a strong, persistent signal of transgene (RFP) expression was evidenced in the samples over extended periods of time (up to 125 days, the longest time point examined) at the optimal concentration of hirudin. Finally, neither administration of rAAV nor of hirudin altered the potential for chondrogenic differentiation in the aspirates and application of a potent candidate gene, the SOX9 transcription factor, was capable of enhancing the chondrogenic differentiation processes in the samples while reducing undesirable hypertrophy, in good agreement with our previous findings when applying rAAV-FLAGhsox9 to isolated MSCs. 22 Taken together, our data show that rAAV vectors are particularly well adapted to deliver gene sequences in primary human bone marrow aspirates in a safe manner over persistent periods of time and without impeding the ability to commit toward the chondrocyte phenotype. Research is ongoing to characterize the population of transduced cells that undergo such chondrogenic processes in the aspirates. It remains to be seen whether too long levels of transgene expression will not be detrimental to the samples. In such a case, the use of regulatable (tetracycline-sensitive) or tissue-specific promoters (SOX9, type-II collagen or cartilage matrix oligomeric matrix protein) [34] [35] [36] [37] rather than the cytomegalovirus immediate-early element may have value to modulate the production of the transgenes. In addition, while AAV-2 has been mostly employed to target MSCs so far, it would be also interesting to examine the benefits of applying other serotypes of the virus in the current system. The next step will be to translate the current strategy in aspirates from animal species to test the ability of the constructs to efficiently and safely promote transgene expression in cartilage defects in vivo and to allow for durably, enhanced cartilage repair upon transplantation of samples modified with our SOX9 rAAV vector in such clinically relevant experimental models. Encouraging results in vivo have been already reported when directly applying the current candidate vector to osteochondral defects in the knee joints of rabbits, showing the ability of this construct to significantly enhance the articular chondrogenic processes in bone marrow and the healing of the lesions, with delayed terminal differentiation and hypertrophy in the newly formed cartilage by opposing effects of the sox9 treatment on RUNX2 and β-catenin expression and with subchondral bone reconstitution by increased RUNX2 expression in this area. 28 Other agents including different transcription factors, 22, 28, 38, 39 TGF-β, 20, 40 bone morphogenetic proteins, [41] [42] [43] [44] [45] insulin-like growth factor I, [46] [47] [48] cartilagederived morphogenetic protein 1 (ref. 49) or zinc-finger protein 145 (ref. 50) might be also good candidates to further enhance chondrogenesis and tissue healing in cartilage lesions. Combined application of various candidates may be even necessary and again, rAAV will be a powerful system to achieve this goal as separate vectors can be simultaneously delivered, allowing for effective co-overexpression of the transgenes applied. 51 The current findings provide strong motivation to further elaborate gene-based protocols for the modification of bone marrow aspirates as a safe, convenient and clinically relevant option to treat articular cartilage defects.
MATERIALS AND METHODS Reagents
All reagents were from Sigma-Aldrich (Munich, Germany) except otherwise indicated. Sodium heparin (5000 IU ml − 1 ) was purchased from B. Braun (Melsungen AG, Germany). Hirudin (Lepirudin, Refludan) was purchased from Celgene (Munich, Germany). The anti-type-II collagen (II-II6B3) antibody was from DSHB (Iowa, IA, USA) and the anti-type-X collagen (COL-10) antibody from Sigma-Aldrich. The anti-SOX9 (C-20) antibody was from Santa Cruz Biotechnology (Heidelberg, Germany). The Beta-Glo Assay System was from Promega. The Cell Proliferation Reagent WST-1 and the Cytotoxicity Detection Kit (LDH) were from Roche Applied Science (Mannheim, Germany).
Culture of bone marrow aspirates
The study was approved by the Ethics Committee of the Saarland Physicians Council. All patients provided informed consent before inclusion in the study. All procedures were in accordance with the Declaration of Helsinki. Bone marrow aspirates (~15 ml) were obtained in the absence of anticoagulant from the distal femur of patients (n = 12) undergoing total knee arthroplasty. Aliquots (150 μl) were immediately and rapidly placed in 96-well plates to test the following conditions: absence of anticoagulant, treatment with sodium heparin (5000 IU ml ). 24, 25 Aspirates were immediately mixed with the vectors or let untransduced and further maintained in DMEM, 100 U ml − 1 penicillin and 100 μl ml − 1 streptomycin, 10% fetal bovine serum at 37°C in a humidified atmosphere with 5% CO 2 for the different experiments at the denoted time points, with medium changes every 2 to 3 days. To evaluate the ability of bone marrow aspirates to undergo chondrogenic differentiation, experiments were performed using optimized treatment and gene transfer conditions in defined medium. Aspirates treated with hirudin (0.5 mg ml − 1 ) were transduced with rAAVlacZ (40 μl) or let untransduced, and maintained for 21 days in chondrogenic medium (DMEM, 0.1 μM dexamethasone, 50 μg ml − 1 ascorbic acid, 40 μg ml − 1 proline, 110 μg ml − 1 pyruvate, 6.25 μg ml − 1 insulin, 6.25 μg ml − 1 transferrin, 6.25 μg ml − 1 selenious acid, 1.25 mg ml − 1 bovine serum albumin, 5.55 μg ml − 1 linoleic acid and 10 ng ml − 1 TGF-β3) 19, 22 for subsequent analyses. Aspirates without hirudin treatment were used as control conditions.
Plasmids and rAAV vectors
The constructs were derived from pSSV9, an AAV-2 genomic clone. 52, 53 rAAV-lacZ carries the lacZ gene for Escherichia coli β-gal, rAAV-RFP a 776-bp Discosoma sp. RFP cDNA fragment and rAAV-FLAG-hsox9 a 1.7-kb FLAGtagged human SOX9 (hsox9) cDNA, all under the control of the cytomegalovirus immediate-early promoter. 18, 19, 22, 28, 51, 54 The vectors were packaged as conventional (not self-complementary) vectors using a helper-free, two-plasmid transfection system in the 293 cell line (an adenovirus-transformed human embryonic kidney cell line) with the packaging plasmid pXX2 and the adenovirus helper plasmid pXX6 as previously described. 54 The vector preparations were purified by dialysis and titered by real-time PCR, 18, 19, 22, 28, 54 averaging 10 10 transgene copies/ ml (ratio virus particles to functional vectors = 500/1).
rAAV gene transfer
The vectors were directly mixed to the bone marrow aspirates using concentrations previously employed for isolated human MSCs (10, 20 or 40 μl, that is 2, 4 or 8 × 10 5 functional recombinant viral particles) 19, 22 or let untreated for up to 125 days.
Transgene expression
Expression of the lacZ transgene was analyzed by X-gal staining and visualization under light microscopy (Olympus BX45; Hamburg, Germany) 18, 19, 28 and using the Beta-Glo assay according to the manufacturer's recommendations, with normalization of the relative luminescence units per aspirate. RFP was detected by live fluorescence using a fluorescent microscopy with a 568-nm filter (Olympus CKX41). 18, 19, 22, 28, 54 Cell proliferation and cytotoxicity analyses Cell proliferation was assessed using the Cell Proliferation Reagent WST-1 (Roche Applied Science) with OD proportional to the cell numbers, as previously described. 19, 22 Cytotoxic events were evaluated using the Cytotoxicity Detection Kit (LDH; Roche Applied Science) by measuring the release of lactate dehydrogenase activity in the supernatants of cultures in accordance with the manufacturer's instructions. 55 Data were generated with a GENios spectrophotometer/fluorometer (Tecan, Crailsheim, Germany) and calculated as the percentage of cytotoxicity using the formula: (experimental value − low control/high control − low control) × 100. Where low control corresponds to cells without assay treatment and high control to cells placed in the lysis buffer provided in the kit.
Histological and immunohistochemical analyses
Aspirates were harvested and fixed in 4% buffered formalin. Fixed aspirates were dehydrated in graded alcohols, embedded in paraffin rAAV gene transfer in human bone marrow aspirates A Rey-Rico et al and sectioned (3 μm) . Sections were stained with toluidine blue (matrix proteoglycans) according to routine protocols. 18, 19, 22, 28, 54 Expression of type-II/type-X collagen and SOX9 was detected using specific primary antibodies and biotinylated secondary antibodies (Vector Laboratories, Alexis Deutschland GmbH, Grünberg, Germany) with the ABC method (Vector Laboratories) and diaminobenzidine as the chromogen. 18, 19, 22, 28, 54 To control for secondary immunoglobulins, samples were processed with omission of the primary antibody. Samples were examined under light microscopy (Olympus BX45).
Morphometric analyses
The transduction efficiencies (ratio of X-gal-stained surface, or areas, to the total surface, or number of areas, evaluated) and the intensities of toluidine blue staining and of type-II/type-X collagen and SOX9 immunostaining were measured at three random standardized sites for each test and replicate condition by using SIS analySIS program (Olympus), Adobe Photoshop (Adobe Systems, Unterschleissheim, Germany) and Scion Image (Scion Corporation, Frederick, MD, USA). 19, 54 The intensities for toluidine blue staining and for type-II/type-X collagen and SOX9 immunostaining were in pixels per standardized area. 19, 54 Statistical analysis
Each condition was performed in duplicate in three independent experiments. Values are expressed as mean ± s.d. The t-test and MannWhitney rank sum test were employed where appropriate. P values o0.05 were considered statistically significant.
